Key result
Specific microRNA dysregulation emerges as a potential biomarker for Chagas disease susceptibility and chronic cardiomyopathy severity.
Why the study?
Chagas disease requires better understanding of molecular mechanisms driving disease progression and identification of biomarkers for susceptibility and cardiomyopathy severity.
Are specific circulating microRNAs associated with Chagas disease susceptibility and chronic Chagas cardiomyopathy severity?
Cross-Sectional (n=192)
Are specific circulating microRNAs associated with Chagas disease susceptibility and chronic Chagas cardiomyopathy severity?
Specific circulating microRNAs are dysregulated in Chagas disease and may serve as potential biomarkers for disease susceptibility and cardiomyopathy severity.
May support microRNA biomarker development in Chagas disease; leaves open prospective validation before clinical use.
BACKGROUND: Chagas disease (ChD), a major public health concern in Latin America, requires better understanding of molecular mechanisms driving disease progression and identification of biomarkers. We investigated circulating microRNAs associated with ChD susceptibility and chronic Chagas cardiomyopathy (CCC) progression. METHODS: In a cross-sectional study of 150 patients with ChD (46 indeterminate, 104 CCC) and 42 non-ChD controls, we performed microRNA sequencing, and differentiated expressed microRNAs (DEMs) were submitted to in silico functional analyses. RESULTS: We identified 40 DEMs between patients with ChD and controls, highlighting upregulated miR-143-3p and miR-223-3p, and downregulated miR-486-5p and miR-3960 in patients with ChD. These miRNAs showed involvement in immune response and cardiovascular signaling pathways. MiR-6734-5p, miR-1285-5p, miR-10527-5p, and miR-1228-5p tended to be upregulated, while miR-30c-3p tended to be downregulated in patients with severe compared to mild CCC. CONCLUSIONS: This study provides evidence for specific microRNA dysregulation in ChD, highlighting their potential as biomarkers of ChD susceptibility and CCC severity.
No takes yet. Share an insight, caveat, or question.
Roma et al. (2026) conducted a cross-sectional in Chagas disease and chronic Chagas cardiomyopathy (n=192). Chagas disease vs. Non-Chagas disease controls was evaluated on Differentially expressed microRNAs (DEMs). Chagas disease was associated with 40 differentially expressed microRNAs compared to controls, highlighting upregulated miR-143-3p and miR-223-3p, and downregulated miR-486-5p and miR-3960.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: